DP-b99

DP-b99 is a lipophilic, cell-permeable small molecule derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), developed as a neuroprotectant. It selectively chelates and modulates the distribution of metal ions such as calcium, zinc, copper and iron in hydrophobic environments like cell membranes. The drug was designed using D-Pharm’s proprietary Membrane Active Chelators (MAC) technology to address disturbances in metal ion homeostasis implicated in neuronal damage following stroke and other acute neurological injuries. Preclinical studies demonstrated neuroprotective effects in models of cerebral ischemia and seizures by inhibiting matrix metalloproteinase activity (notably MMP-9), reducing neuronal loss and modulating inflammatory responses. Clinical development included phase 3 trials for acute ischemic stroke; however, these did not demonstrate efficacy for that indication. Additional studies explored its use in traumatic brain injury and acute high-risk pancreatitis[1][2][4][5][6][8].

Other names

1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid N,N′-di(octyloxyethyl ester) N,N′-disodium salt